{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:26:22Z","timestamp":1787109982381,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejps.2026.107610","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T15:25:36Z","timestamp":1784388336000},"page":"107610","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Inhaled product dissolution as a predictive tool of drug bioavailability: a p38 MAPK inhibitor case study using Respicell\u00ae dissolution apparatus"],"prefix":"10.1016","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0522-8303","authenticated-orcid":false,"given":"Virginia","family":"Patterlini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marenghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0922-7134","authenticated-orcid":false,"given":"Alessandro","family":"Fioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Trevisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Pio","family":"Mazzeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0215-2350","authenticated-orcid":false,"given":"Eride","family":"Quarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4472-4823","authenticated-orcid":false,"given":"Francesca","family":"Buttini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7372-1456","authenticated-orcid":false,"given":"Fabio","family":"Sonvico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2026.107610_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114468","article-title":"Solid state of inhalable high dose powders","volume":"189","author":"Adhikari","year":"2022","journal-title":"Adv. Drug Deliver. Rev."},{"key":"10.1016\/j.ejps.2026.107610_bib0002","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s12964-023-01337-4","article-title":"p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics","volume":"21","author":"Ahmadi","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejps.2026.107610_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123151","article-title":"Quality by design \u2013 Spray drying of ciprofloxacin-quercetin fixed-dose combination intended for inhalation","volume":"642","author":"Alhajj","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107610_bib0004","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.xphs.2021.09.042","article-title":"In-vitro In-vivo correlation (IVIVC) of inhaled products using twin stage impinger","volume":"111","author":"Ayoub","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107610_bib0005","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1021\/acs.molpharmaceut.2c00112","article-title":"iBCS: 2. mechanistic modeling of pulmonary availability of inhaled drugs versus critical product attributes","volume":"19","author":"B\u00e4ckman","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2026.107610_bib0006","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1208\/s12248-015-9760-6","article-title":"Pharmacometric models for characterizing the pharmacokinetics of orally inhaled drugs","volume":"17","author":"Borghardt","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2026.107610_bib0007","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jconrel.2012.02.028","article-title":"Particles and powders: tools of innovation for non-invasive drug administration","volume":"161","author":"Buttini","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2026.107610_bib0008","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijpharm.2014.01.033","article-title":"Differences in physical chemistry and dissolution rate of solid particle aerosols from solution pressurised inhalers","volume":"465","author":"Buttini","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107610_bib0009","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejps.2017.10.042","article-title":"The application of quality by design framework in the pharmaceutical development of dry powder inhalers","volume":"113","author":"Buttini","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107610_bib0010","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2174\/138920012800166571","article-title":"Optimisation of DMPK by the inhaled route: challenges and approaches","volume":"13","author":"Cooper","year":"2012","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2026.107610_bib0011","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ijpharm.2016.06.029","article-title":"The influence of lung surfactant liquid crystalline nanostructures on respiratory drug delivery","volume":"514","author":"Das","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107610_bib0012","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3390\/pharmaceutics14122667","article-title":"Dissolution and absorption of inhaled drug particles in the lungs","volume":"14","author":"Eedara","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107610_bib0013","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/jamp.2017.1369","article-title":"Investigation of lung pharmacokinetic of the novel PDE4 inhibitor CHF6001 in preclinical models: evaluation of the PreciseInhale technology","volume":"31","author":"Fioni","year":"2018","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ejps.2026.107610_bib0014","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1021\/acs.molpharmaceut.4c01534","article-title":"iBCS: 4. application of the inhalation biopharmaceutics classification system to the development of orally inhaled drug products","volume":"22","author":"Forbes","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2026.107610_bib0015","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.1021\/jm1005989","article-title":"Inhalation by design: novel ultra-long-acting \u03b22-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup","volume":"53","author":"Glossop","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2026.107610_bib0016","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1021\/acs.molpharmaceut.3c00685","article-title":"iBCS: 3. a biopharmaceutics classification system for orally inhaled drug products","volume":"21","author":"Hastedt","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2026.107610_bib0017","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1021\/acs.molpharmaceut.2c00113","article-title":"iBCS: 1. principles and framework of an inhalation-based Biopharmaceutics classification system","volume":"19","author":"Hastedt","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2026.107610_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2011.08.032","article-title":"Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications","volume":"420","author":"Kawabata","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107610_bib0019","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejpb.2013.02.014","article-title":"Towards the bioequivalence of pressurised metered dose inhalers 1: design and characterisation of aerodynamically equivalent beclomethasone dipropionate inhalers with and without glycerol as a non-volatile excipient","volume":"86","author":"Lewis","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2026.107610_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105341","article-title":"Pulmonary delivery of a p38 \u03b1\/\u03b2 MAP kinase inhibitor: bioanalytical method validation and biodistribution in rat plasma and respiratory tissues","volume":"149","author":"Marenghi","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107610_bib0021","doi-asserted-by":"crossref","first-page":"15","DOI":"10.14227\/DT180311P15","article-title":"Simulated biological fluids with possible application in dissolution testing","volume":"18","author":"Marques","year":"2011","journal-title":"Dissolution Tech."},{"key":"10.1016\/j.ejps.2026.107610_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115331","article-title":"Application of an \u201cinhalation by design\u201d approach to the identification and in-vitro evaluation of novel purine based PI3K\u03b4 inhibitors","volume":"254","author":"Mazzucato","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejps.2026.107610_bib0023","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1021\/jm200677b","article-title":"Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease","volume":"54","author":"Millan","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2026.107610_bib0024","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3390\/pharmaceutics15030983","article-title":"In vitro dissolution and permeability testing of inhalation products: challenges and advances","volume":"15","author":"Nokhodchi","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107610_bib0025","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1517\/13543784.2015.1006358","article-title":"Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease","volume":"24","author":"Norman","year":"2015","journal-title":"Exp. Opin. Invest. Drugs"},{"key":"10.1016\/j.ejps.2026.107610_bib0026","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3390\/pharmaceutics16080989","article-title":"Clinically relevant characterization and comparison of Ryaltris and other anti-allergic nasal sprays","volume":"16","author":"Patterlini","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107610_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120893","article-title":"Impact of simulated lung fluid components on the solubility of inhaled drugs and predicted in vivo performance","volume":"606","author":"Radivojev","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107610_bib0028","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijpharm.2018.11.072","article-title":"Searching for physiologically relevant in vitro dissolution techniques for orally inhaled drugs","volume":"556","author":"Radivojev","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107610_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106158","article-title":"Particle engineering in dry powders for inhalation","volume":"172","author":"Scherlie\u00df","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107610_bib0030","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1089\/jamp.2012.0971","article-title":"Dry powder inhalation exposures of the endotracheally intubated rat lung, ex vivo and In vivo: the pulmonary pharmacokinetics of Fluticasone Furoate","volume":"26","author":"Selg","year":"2013","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ejps.2026.107610_bib0031","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/17425247.2023.2205636","article-title":"The importance of dissolution for orally inhaled drug products: pharmaceutical, regulatory, and clinical considerations","volume":"20","author":"Somby","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejps.2026.107610_bib0032","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.3390\/pharmaceutics13101541","article-title":"RespiCellTM: an innovative dissolution apparatus for inhaled products","volume":"13","author":"Sonvico","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107610_bib0033","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.xphs.2020.09.006","article-title":"Contemporary formulation development for inhaled pharmaceuticals","volume":"110","author":"Sou","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107610_bib0034","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejps.2017.09.002","article-title":"Dry powder inhalers: an overview of the in vitro dissolution methodologies and their correlation with the biopharmaceutical aspects of the drug products","volume":"113","author":"Velaga","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107610_bib0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-3659(99)00230-8","article-title":"Drug solubilization in lung surfactant","volume":"65","author":"Wiedmann","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2026.107610_bib0036","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.4155\/fmc.11.97","article-title":"The paradox of respiratory R&D, and why inhaled-by-design heralds a new dawn in asthma and chronic obstructive pulmonary disease treatments","volume":"3","author":"Yeadon","year":"2011","journal-title":"Futur. Med. Chem."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726001843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726001843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T02:42:31Z","timestamp":1787107351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726001843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"alternative-id":["S0928098726001843"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107610","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhaled product dissolution as a predictive tool of drug bioavailability: a p38 MAPK inhibitor case study using Respicell\u00ae dissolution apparatus","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107610","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107610"}}